PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Tang, Kun
Jiang, Kehua
Zhou, Hui
Liu, Haoran
Ye, Zhangqun
Xu, Hua
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP78-09
引用
收藏
页码：E1040 / E1040
页数：1
相关论文
共 50 条
  • [31] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    Patrinely, James Randall, Jr.
    Dewan, Anna K.
    Johnson, Douglas B.
    BIODRUGS, 2020, 34 (04) : 495 - 503
  • [32] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    James Randall Patrinely
    Anna K. Dewan
    Douglas B. Johnson
    BioDrugs, 2020, 34 : 495 - 503
  • [33] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Li, Yuegang
    Du, Yuwei
    Xue, Chi
    Wu, Pei
    Du, Nan
    Zhu, Guolian
    Xu, Huimian
    Zhu, Zhi
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [34] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Yuegang Li
    Yuwei Du
    Chi Xue
    Pei Wu
    Nan Du
    Guolian Zhu
    Huimian Xu
    Zhi Zhu
    BMC Gastroenterology, 22
  • [35] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [36] Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis
    Fu, Hanlin
    Fu, Zhihui
    Mao, Meng
    Si, Lulu
    Bai, Jing
    Wang, Qian
    Guo, Ruixia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 189
  • [37] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
    Zhang, Yiru
    Yao, Qigu
    Pan, Yong
    Fang, Xinru
    Xu, Haoying
    Zhao, Tingxiao
    Zhu, Guangqi
    Jiang, Tianan
    Li, Shibo
    Cao, Hongcui
    CANCERS, 2023, 15 (03)
  • [38] Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis
    Nie, Run-Cong
    Duan, Shu-Qiang YuanJin-Ling
    Liang, Yao
    Chen, Xiao-Jiang
    Chen, Yong-Ming
    Luo, Tian-Qi
    Chen, Guo-Ming
    Wang, Yun
    Li, Yuan-Fang
    IMMUNOTHERAPY, 2020, 12 (18) : 1313 - 1324
  • [39] Cabozantinib in patients with locally advanced or metastatic urothelial cell carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only.
    Bartsch, Georg
    Thomas, Christian
    Tsaur, Igor
    Schnabel, Marco
    Haferkamp, Axel
    Gorbulev, Stanislav
    Ruckes, Christian
    Kronfeld, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis
    Paderno, Alberto
    Petrelli, Fausto
    Lorini, Luigi
    Capriotti, Vincenzo
    Gurizzan, Cristina
    Bossi, Paolo
    ORAL ONCOLOGY, 2024, 153
12345